Skip Navigation

European Heart Journal 2004 25(8):631-633; doi:10.1016/j.ehj.2004.02.025
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Spinale, F. G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spinale, F. G
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Matrix metalloproteinase gene polymorphisms in heart failure: new pieces to the myocardial matrix puzzle

Francis G Spinale*

Cardiothoracic Surgery, Room 625, Medical University of South Carolina, Strom Thurmond Research Building, 770 MUSC Complex, 114 Doughty Street, Charleston, SC 29425, USA

* Tel.: +1-843-876-5184/5186; fax: +1-843-876-5187
E-mail address: wilburnm@musc.edu

The first 10% of the full text of this article appears below.

This editorial refers to "Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction"1 by Bauters et al. on page 688

An important structural milestone in patients with progressive heart failure is myocardial remodelling, although the inciting stimuli can be diverse. Pharmacological interventions targeted at altering this adverse left ventricular (LV) myocardial remodelling process hold therapeutic promise. However, designing an appropriate therapeutic regimen for interrupting the progression of myocardial remodelling requires an understanding of the basic molecular and cellular mechanisms that drive this process. Myocardial remodelling can be defined as the changes that occur within both the cellular and extracellular compartments and result in alterations in LV myocardial and chamber geometry. It is now well recognised that changes in the myocardial extracellular matrix contribute to the progressive remodelling process. Therefore, the identification . . . [Full Text of this Article]

Matrix metalloproteinases (MMPs) and the heart failure process

MMP transcriptional control and gene polymorphisms


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction
Frédérique Mizon-Gérard, Pascal de Groote, Nicolas Lamblin, Xavier Hermant, Jean Dallongeville, Philippe Amouyel, Christophe Bauters, and Nicole Helbecque
EHJ 2004 25: 688-693. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
S. Ye
Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome
Cardiovasc Res, February 15, 2006; 69(3): 636 - 645.
[Abstract] [Full Text] [PDF]